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ABSTRACT 54 
Background: In our recent village-based cross-sectional study, the prevalence of nucleic acid 55 
amplification technique (NAAT) diagnosed Chlamydia trachomatis (CT) in sexually active 56 
Samoan women was very high (36%), and test positivity was associated with sub-fertility. 57 
We conducted a serological and epidemiological analysis in these participants to identify if 58 
serological data can provide further insight into the potential contribution of CT to sub-59 
fertility in this population. 60 
Methods: Serological prediction of CT associated sub-fertility was conducted using a series 61 
of commercial tests. The correlation between fertility or sub-fertility, behavioral factors, and 62 
serologically predicted CT associated sub-fertility was determined.  63 
Results: A positive antibody reaction against the Chlamydia Major Outer Membrane Protein 64 
(MOMP) was significantly associated with sub-fertility, with 50% of infertile women being 65 
positive. Serum IgG and IgA antibodies against MOMP correlated with current infection 66 
measured by urine NAAT, suggesting longer term infections are common in this population. 67 
Chlamydia pneumoniae antibodies were frequently detected in this population (84%), and 68 
unexpectedly, were significantly associated with sub-fertility. 69 
Conclusions: The high prevalence of chlamydial infection and of positive chlamydial sub-70 
fertility results suggests that CT is an important and frequent contributory factor to sub-71 




Chlamydia trachomatis (CT) is the most common bacterial sexually transmitted infection 76 
(STI) in the world. The infection can result in the development of serious sequelae such as 77 
pelvic inflammatory disease (PID), ectopic pregnancy and tubal factor infertility (TFI) in 78 
women. The reported prevalence of CT infection is in the range 1.4–8.7 % when  the general 79 
population in high income countries is screened [1-3]. The prevalence of CT infection in 80 
Samoa was previously estimated by Sullivan et al.  [4] to be 30.9% based on antenatal 81 
screening. Similarly, in women who attended antenatal clinics between 2004 and 2005 in the 82 
Pacific Islands (Fiji, Kiribati, Samoa, Solomon Islands, Tonga, and Vanuatu), CT prevalence 83 
was 26.1% in women under 25 years old, and 11.9% in women over 25 [5].  84 
The proportion of infertility attributable to CT in the Samoan population is not known. Such 85 
infertility results from tissue damage to the fallopian tubes (tubal factor infertility, TFI) that 86 
remains after the active infection is cleared, meaning that diagnosis using nucleic acid 87 
amplification tests (NAAT) is not necessarily suitable. There are numerous serological or 88 
chlamydia antibody tests (CAT) that have been developed to diagnose CT infertility, that 89 
have been validated on cohorts of women with evidence of tubal damage detected by 90 
hysterosalpingography or laparoscopy [6-11]. In a meta-analysis of published evaluations of 91 
various assays, Broeze and co-workers identified that micro immune-fluorescence (MIF) was 92 
the most sensitive, but relatively low in specificity [6]. In the same study the MEDAC and 93 
ANIlabsystems enzyme linked immunosorbant assays (ELISA) appeared to most specific, 94 
although less sensitive than MIF, to diagnose women with uni or bi-lateral tubal damage 95 
detected by surgical or sonographic technologies [6]. However, a proportion of women with 96 
infertility and who are serologically positive by CAT have no detectable tubal blockage but 97 
still require IVF (in vitro fertilization) to conceive, and this could be at least partially due to 98 
tubal damage not detectable by the current surgical or sonographic methods [12-14].  In 99 
lower and middle income countries (LMIC) studies generally report higher prevalence of CT 100 
in infertile or sub-fertile women (39-55%), although the prevalence of CT infection in fertile 101 
women is also generally high [15-17].   102 
 103 
We recently reported a high prevalence (36.0% by NAAT) of CT in Samoan women using 104 
community-based screening and survey of sexually active women aged 18–29 years having 105 
unprotected sex, and current infection was associated with women who were defined as being 106 
sub-fertile  [18]. Here, we conducted a serological study to evaluate the prevalence of CT 107 




The study design and sampling protocol has been previously reported [18]. Women (n=239) 112 
were recruited into a cross-sectional study on CT and sub-fertility from the Pacific nation of 113 
Samoa during 2011. Participant inclusion criteria were age between 18 and 29 years, living in 114 
the village for at least a year and being sexually active without using any forms of 115 
contraception (including condoms, birth control pills, or other forms of contraception) for at 116 
least a year. Women were excluded if they had a medical condition, or had undergone a 117 
procedure that made it impossible to become pregnant. Participants provided informed 118 
written consent, completed an interviewer-led questionnaire and provided biological samples.  119 
The nurse who conducted the interview asked the sexual behavioral questions using socially 120 
acceptable language and used a two step approach to gauge sexual behavior (as previously 121 
described) [18]. The questionnaire responses were used to assign women to ‘sub-fertile’ (or 122 
otherwise ‘fertile’). Sub-fertility was defined as at least 12 months of unprotected intercourse 123 
without conceiving a pregnancy [18]. The NAAT results have been previously analysed and 124 
presented [18], all participants provided a urine specimen that was analysed for CT infection 125 
status using the BD ProbeTec ET assay in accordance with the manufacturer’s instructions 126 
and using positive and negative controls (BD Biosciences, USA) [18]. 127 
 128 
The participant sera were tested for CT antibodies using the following commercial 129 
ELISAs: CT-IgG ELISA-plus MEDAC (peptides from the MOMP protein, referred to as 130 
MEDAC MOMP, used to diagnose past or current infection), cHSP60-IgG ELISA MEDAC 131 
(cSHP60 protein), ANIlabsystems CT IgG (peptides from MOMP, marketed to diagnose CT 132 
infertility), CT IgA ELISA MEDAC (used to diagnose current CT infection), Chlamydia 133 
pneumoniae (CP)-IgG-ELISA MEDAC (used to diagnose current CP infection) (summarized 134 
in Table 1). The assay positive or negative results in accordance with the manufacturer’s 135 
instructions were used for this study (positive, negative, unequivocal (excluded), invalid 136 
(excluded)). Titres were not included in this study as they are not part of these commercial 137 
tests. All sera were tested with all assays, however, any that were unequivocal or invalid 138 
more than once were excluded from the data for that assay and any participants that did not 139 
have a complete dataset and valid test result in every assay were completely excluded from 140 
the analysis in Table 2 and Fig 2. The serological testing of CT associated sub-fertility is 141 
difficult because the gold standard (MIF) has low specificity leading to high false positives 142 
(although it had the highest accuracy using area under the curve), but is reported to be highly 143 
subjective and labor intensive [6]. Therefore we chose to test the population using ELISA as 144 
we prioritised highest specificity in order to indicate the amount of CT associated sub-fertility 145 
in Samoa, and a format that could enable us to compare several tests in a timely manner. We 146 
selected multiple ELISAs to compare the different IgG responses and we also included IgA to 147 
indicate how many of the infections were recent. Finally, we included a Chlamydia 148 
pneumoniae ELISA to enable comparison of the sero-prevalence of a related and very 149 
common pathogen.   150 
All statistical analyses were conducted in R statistical environment (3.0.3) using the 151 
‘EpiR (0.9-57) and 'metafor' package (1.9-2) for calculation and presentation (forest plots) of 152 
odds ratios (OR). All analyses were conducted to measure the association of assay results 153 
with sub-fertility. OR and 95% confidence intervals (CI) were calculated with restricted 154 
maximum likelihood estimates of error.  155 
 156 
RESULTS  157 
Antibody test results for CT associated sub-fertility 158 
239 women meeting the inclusion and exclusion criteria participated in the study; 90 were 159 
defined as being sub-fertile and 149 were defined as fertile with a history of having had a 160 
pregnancy. The association of CT with sub-fertility was analysed using each of the 161 
commercial serological assays. As shown in Fig 1A, women who were sub-fertile were 162 
significantly more likely to have a positive serological reaction in the MEDAC MOMP assay 163 
(p=0.045). 42 out of 82 sub-fertile women were positive in the MEDAC MOMP assay, 164 
whereas 52 out of a total of 139 fertile women were positive. It is important to note that 34 165 
sub-fertile women have been excluded for this assay from Fig 1A because they had 166 
unequivocal results. One of the most common immunological reactions that was associated 167 
with infertility in previous studies [9, 12], an antibody response to cHSP60, was not 168 
significantly associated with sub-fertility: the sero-prevalence of antibodies to cHSP60 did 169 
not differ based on fertility with 57% of both infertile and fertile women being positive (44 170 
out of 76 sub-fertile women were positive and 73 out of 129 fertile women were positive). 171 
The MEDAC Infertile assay, which is recommended by the manufacturer to be a positive 172 
reaction in both the MEDAC MOMP and MEDAC cHSP60 assays, was not significantly 173 
associated with sub-fertility in this study (in the infertile group 29 women were positive out 174 
of 74 total who had results in the assay, and 36 were positive out of a total of 127 women 175 
with reportable results in the fertile group). 176 
 177 
The overall IgG sero-positivity to CT in this population was 43% according to the MEDAC 178 
MOMP results, and 50% according to the ANIlab assay. The numbers reported in Fig. 1 vary 179 
depending on the number of women that had consistent reportable results in the assay (i.e. we 180 
did not include unequivocal or invalid results, these are indicated to the left of the figure).  181 
We included testing for a common respiratory pathogen (Chlamydia pneumoniae) to provide 182 
an indication of serological responses in our population tested. Women who were sub-fertile 183 
were significantly more likely to have a positive reaction in MEDAC CP assay (p<0.001) 184 
(Fig. 1A). The overall presence of sero-positivity to this pathogen (CP) was 86%. A positive 185 
urine NAAT result did not correlate with a positive CP serological result, supporting that this 186 
assay is not likely to be detecting CT cross reactivity. Although, pairwise analysis did show 187 
that MEDAC MOMP positivity significantly correlated with MEDAC CP (chisel p=0.042), 188 
meaning that women positive in MEDAC MOMP were more likely to be positive in MEDAC 189 
CP (OR 3.63 [95% CI: 0.92-21.11]).  190 
 191 
We previously reported that the current infection by urine NAAT was 36% in this cohort 192 
[18], therefore, we evaluated if the serological results correlate with current infection status. 193 
Women who were NAAT positive were significantly more likely to be positive in the 194 
serological assays for CT by all of assays tested (Fig. 1B.). The high association of IgG 195 
against MOMP and cHSP60 and current infection by urine NAAT in this cohort could imply 196 
these are longer term infections, consistent with the lack of STI screening and treatment 197 
programs in this country. A positive result in the MEDAC IgA significantly correlated with 198 
NAAT positive status (Fig 1B) (p=0.004). This higher frequency of IgG (compared to IgA) 199 
correlating with NAAT diagnosed current infection further supports the possibility that in this 200 
population there are frequent repeat or longer term infections, given that IgA tends to be 201 
produced early and in primary infections. 202 
 203 
In the evaluation of demographic factors in relation to subfertility and serological results, we 204 
only included data for participants that had a recordable result in every test and answered 205 
every demographic question (n=162). The details of the participants excluded from this 206 
analysis are provided in Table 2, and there were no significant differences in the sub-fertility 207 
status or other factors in those excluded compared to those included. Age (older women were 208 
more likely to be fertile, p<0.010), MEDAC MOMP (p=0.040), NAAT positive for CT 209 
(p=0.003) and MEDAC CP (p=0.007) were all significant factors that associated with sub-210 
fertility in this subset of participants (Table 3).  211 
 212 
We used the same subset of specimens to assess test concordance. As shown in the Venn 213 
diagram (Fig. 2.) there was often concordance between the serological assays and NAAT 214 
results, particularly between NAAT, MEDAC MOMP, and ANIlab. This supports the notion 215 
that these assays are reporting serological responses to CT and are not likely to be a 216 
consequence of non-specific reactivity.    217 
 218 
DISCUSSION 219 
The results of this study imply that up to half (51% infertile women positive for MEDAC 220 
MOMP) of women who are sub-fertile in this population could have CT as a cause or 221 
contributing factor. To our knowledge this is one of the highest burdens of CT associated 222 
sub-fertility reported to date. This is higher than most studies report, even those conducted in 223 
fertility clinics, but is consistent with a fertility clinic study in India that found a similar 224 
prevalence [15]. This may be a reflection of the absence of routine screening and treatment 225 
for CT infections in this population.  226 
A possible limitation of our study is that the serological results may be influenced by a higher 227 
number of repeat infections given the high prevalence of infection in this population. These 228 
repeat infections may lead to higher positives in these assays which use absorbance 229 
thresholds that have been designed on clinically defined infertile cohorts, often in settings 230 
with a much lower background prevalence. The MEDAC Infertile assay was not significantly 231 
associated with sub-fertility in this study. Nevertheless, the high prevalence of cHSP60 232 
antibodies (one of the components of the MEDAC test) could suggest that chronic infections 233 
or sequelae are high in this population. Most studies that found a significant association had 234 
TFI as the specified measure for infertility [9]. In this population we have limited knowledge 235 
of the other fertility factors as this was a village-based survey in the absence of any 236 
gynecological investigations that would normally be conducted in a fertility clinic. In 237 
addition it is of course possible, considering the sensitivities of obtaining sexual behavior 238 
information that some women were mis-classified with respect to subfertility. The amount of 239 
sexual activity was of course not the same for each woman, affecting their individual 240 
probabilities of becoming pregnant.  241 
The study findings indicated a higher fertility rate in the older ages (although the inclusion 242 
criteria were limited to the most reproductive years). The higher fertility in the older women 243 
is not that unexpected and is likely because this study is based on sexually active women who 244 
were all within the ideal reproductive age, so the longer the period of sexual activity the more 245 
likely the women are to have conceived. Alternatively, this could be explained by an 246 
increased desire of these women (25-29 year olds) to achieve pregnancy leading to increased 247 
sexual activity.   248 
 249 
It was unexpected to find a significant correlation of sero-positivity to C. pneumoniae with 250 
sub-fertility in this population. It is difficult to determine if this is actually serological cross 251 
reactivity (or a genuine association).  Serology to C. pneumoniae, or the presence of the 252 
organism, has been previously found to significantly correlate with various diseases [19-21], 253 
but not with sub-fertility. One possible explanation for this finding could be that the infertile 254 
women in this population have tissue lesions or adhesions in the fallopian tube that may form 255 
a reservoir for the pathogen and perhaps the immune response to this reserve of CP may 256 
exacerbate the CT pathology that results in development of tubal sub-fertility. This 257 
persistence in the scarring site could explain the high prevalence of CP serology that, whilst 258 
significant, is not causal for sub-fertility. Alternatively, this could be a chance result. Firstly, 259 
as the prevalence of Chlamydia pneumoniae antibodies is very high (in both fertile and 260 
infertile women), statistical analysis tends to lead to an overestimation of the odds ratio. 261 
Secondly, the number of participants included in the analysis is relatively low (n=233). 262 
MEDAC MOMP and MEDAC CP were the only assays that significantly correlated with 263 
sub-fertility, suggesting that whilst serology is a much more feasible manner to measure 264 
possible chlamydial infertility in the developing world setting the current assays may be 265 
confounded by the high prevalence, and only MEDAC MOMP may be suitable. 266 
 267 
CONCLUSIONS 268 
The high prevalence of C. trachomatis infections in Samoa is likely to be leading to high 269 
rates of preventable sub-fertility in this population. The results reported here using 270 
serological and epidemiological data collection indicate that CT-associated sub-fertility could 271 
be a factor for as much as half of the burden of sub-fertility in sexually active women in this 272 
reproductive age range in Samoa.  273 
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 406 
  407 
Figure Legends 408 
 409 
Fig. 1. Analysis of the association of serological responses to Chlamydia with fertility 410 
and CT infection status. A. The figure shows Forest plots and Odds Ratio of the association 411 
of a positive reaction in the serological assay listed to the right with being infertile. The assay 412 
is indicated in the left column. The number of participants that were positive or negative in 413 
the serum assay(s) according to their fertile or infertile status are shown on the figure. All 239 414 
participant specimens were tested in each assay. Samples that were unequivocal or not 415 
reproducible upon multiple testing were excluded for each assay and these are indicated in 416 
the column titled invalid/unequivocal on the table.  417 
B. The number of participants positive or negative in each serological assay, grouped 418 
according to also being positive or negative for current CT infection by urine NAAT 419 
(Chlamydia +/-) are shown on the figure. OR with 95% CI and P values are indicated at the 420 
right of the figures. 421 
 422 
Fig 2. Venn diagram to demonstrate concordance between serological assays and CT 423 
NAAT results. The diagram shows the number of participants positive in each of the assays 424 
and those who were positive in more than one assay. The two MOMP assays (MEDAC IgG 425 
and ANIlab) and NAAT results showed considerable concordance. The samples that were 426 
negative in all assays are also indicated on the figure, only the 162 samples that had a valid 427 
result in all of these assays are included in the Venn diagram. 428 
  429 
Table 1.  Commercial serological assays and previously reported sensitivity and 430 
specificity 431 
Assay name Antigen Study 
reference 
name 
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n OR (95% c.i.) 
P value 
for OR 
Age     
  18-24 97 48 1  
  25-29 64 29 1.11 (0.63-1.94) 0.720 
Smoking     
  Never 129 59 1  
  Ex-smoker/current 33 18 0.84 (0.44-1.61) 0.600 
Fertility Status     
  Sub-fertile 59 28 1  
  Fertile 103 49 1.00 (0.57-1.75) 0.990 
 437 
 438 
Comparison of Age, smoking and fertility status for participants included or excluded in the 439 
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n2@ OR (95% c.i.) 
P value 
for OR 
Age     
  18-24 47 50 1  
  25-29 12 53 0.24 (0.11-0.51) <0.01 
BMI     
  Normal Weight 12 21 1  
  Overweight 27 35 0.74 (0.31-1.80) 0.498 
  Obese 20 47 0.74 (0.31-1.80) 0.512 
Smoking     
  Never 46 83 1  
  Ex-
smoker/current 13 20 1.17 (0.53-2.57) 0.691 
MEDAC Infertile    
  Negative 34 72 1  
  Positive 25 31 1.71 (0.88-3.33) 0.115 
MEDAC MOMP    
  Negative 28 66 1  
  Positive 31 37 1.97 (1.03-3.78) 0.040 
MEDAC cHSP60    
  Negative 25 41 1  
  Positive 34 62 0.9 (0.47-1.72) 0.749 
MEDAC IgA     
  Negative 49 89 1  
  Positive 10 14 1.3 (0.55-3.14) 0.563 
ANIlab     
  Negative 29 59 1  
  Positive 30 44 1.39 (0.73-2.64) 0.318 
MEDAC CP    
  Negative 2 22 1  
  Positive 57 81 7.74 (1.75-34.21 0.007 
CT Infection 
(NAAT)     
  Negative 28 73 1  
  Positive 31 30 2.69 (1.39-5.24) 0.003 
@ This table only includes women who had consistent results in all assays (n=162), 59 sub-448 
fertile and 103 fertile women. 449 
 450 
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 452 
Fig. 1. Analysis of the association of serological responses to Chlamydia with fertility 453 










Fig 2. Venn diagram to demonstrate concordance between serological assays and CT 464 
NAAT results.  465 
